Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance

被引:121
作者
Chang, HW
Chow, V
Lam, KY
Wei, WI
Yuen, APW
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
tongue carcinoma; hypermethylation; methylation; E-cadherin;
D O I
10.1002/cncr.10211
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
BACKGROUND. E-cadherin is expressed on the surface of normal epithelial cells, Loss of E-cadherin expression has been found in cancers and is postulated to facilitate tumor cell dissociation and metastasis. This study evaluated the role of promoter dense methylation in the downregulation of E-cadherin expression in oral tongue carcinoma. METHODS. E-cadherin expression of 109 oral tongue carcinomas (93 primary tumors, 7 locally recurrent tumors, and 9 metastatic lymph nodes) was evaluated by immunohistochemical staining of tumor tissues, The methylation status of the CpG islands at the promoter region of F-cadherin which flanked five HpaII (methylation sensitive restriction enzyme) digestion sites were evaluated by methylation sensitive polymerase chain reaction in 86 tumors (70 primary, tumors, 7 locally recurrent tumors, and 9 metastatic lymph nodes). RESULTS. Underexpression of E-cadherin was found in 83% of primary tumors, 86% of recurrent tumors, and 89% of nodal metastases. Hypermethylated E-cadherin promoter was found in 64% of primary tumors, 71% of recurrent tumors, and 67% of nodal metastases. Downregulation of E-cadherin expression was found to be related to promoter hypormethylation. Consistently weak expression of E-cadherin by promoter hypermethylation was observed in primary tumors, their corresponding metastatic lymph nodes, and recurrent tumors, Downregulation of E-cadherin expression was a significant poor prognostic factor for survival. CONCLUSIONS. Methylation of CpG sites at the promoter region played a key role in the inhibition of E-cadherin expression in both primary oral tongue carcinomas and their corresponding recurrences and nodal metastases. The resulting downregulation of E-cadherin expression had adverse effects on the prognosis, of patients who were treated by primary surgery. (C) 2002 American Cancer Society.
引用
收藏
页码:386 / 392
页数:7
相关论文
共 36 条
[1]
THE E-CADHERIN PROMOTER - FUNCTIONAL-ANALYSIS OF A G.C-RICH REGION AND AN EPITHELIAL CELL-SPECIFIC PALINDROMIC REGULATORY ELEMENT [J].
BEHRENS, J ;
LOWRICK, O ;
KLEINHITPASS, L ;
BIRCHMEIER, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (24) :11495-11499
[2]
Chan MF, 2000, CURR TOP MICROBIOL, V249, P75
[3]
X-chromosome inactivation analysis of isolated Reed-Sternberg cells in nodular sclerosing Hodgkin's disease [J].
Chang, HW ;
Chong, SM ;
Peh, SC ;
Lee, SH .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (03) :641-647
[4]
A comparative study of the clinicopathological significance of E-cadherin and catenins (α,β,γ) expression in the surgical management of oral tongue carcinoma [J].
Chow, V ;
Yuen, APW ;
Lam, KY ;
Tsao, GSW ;
Ho, WK ;
Wei, WI .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (01) :59-63
[5]
Sp1 binding is inhibited by (m)Cp(m)CpG methylation [J].
Clark, SJ ;
Harrison, J ;
Molloy, PL .
GENE, 1997, 195 (01) :67-71
[6]
A GENOMIC SEQUENCING PROTOCOL THAT YIELDS A POSITIVE DISPLAY OF 5-METHYLCYTOSINE RESIDUES IN INDIVIDUAL DNA STRANDS [J].
FROMMER, M ;
MCDONALD, LE ;
MILLAR, DS ;
COLLIS, CM ;
WATT, F ;
GRIGG, GW ;
MOLLOY, PL ;
PAUL, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1827-1831
[7]
Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression [J].
Graff, JR ;
Gabrielson, E ;
Fujii, H ;
Baylin, SB ;
Herman, JG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (04) :2727-2732
[8]
Graff JR, 1998, CANCER RES, V58, P2063
[9]
GRAFF JR, 1995, CANCER RES, V55, P5195
[10]
Gray SG, 1999, INT J MOL MED, V4, P333